The end of the year should see a flurry of new products reaching the market to break new commercial ground or shake up their respective therapeutic areas. Here, Scrip takes a look at 12 of the more interesting approvals expected in the coming months, with the help of analysts at Biomedtracker. Supernus Pharmaceuticals’ SPN-812 Indication: … Continue reading “Sanofi, Pfizer & Bristol Drugs Among the 12 Approvals to Look Out for in Q4”
Author: Alex Shimmings
Alex Shimmings is managing editor of Scrip.